首页> 外文期刊>Journal of Clinical Microbiology >Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.
【24h】

Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.

机译:患有一种或多种感染发作的艾滋病和口腔念珠菌病患者的多个白色念珠菌菌落的氟康唑敏感性和DNA亚型变化。

获取原文
           

摘要

Five Candida albicans colonies from each infection in AIDS patients receiving fluconazole therapy for oropharyngeal candidiasis over a 2-year period were evaluated by antifungal susceptibility testing and DNA subtyping, and the results were correlated with clinical response to determine the occurrence of clinically significant selection of more-resistant C. albicans over multiple infections. A total of 534 C. albicans isolates were obtained from 38 patients who exhibited 84 episodes of infection. Antifungal susceptibility testing revealed that the MICs for 93% of the isolates were < or = 8.0 microg/ml and the MICs for 7% of the isolates were > or = 64 microg/ml. DNA subtyping revealed 70 different subtypes, with 78% of patients with one infection exhibiting one DNA subtype and 80% of patients with more than one infection exhibiting multiple DNA subtypes. Also, patients who had multiple infections had lower CD4 counts than those with single infections. Differences between the single-infection group and the multiple-infection group regarding the number of DNA subtypes and CD4 counts were both statistically significant. Of the 74 evaluable infections all were successfully treated with regular-dose (100-mg/day) fluconazole, except for three patients who ultimately responded to higher-dose fluconazole. Only one patient may have shown clinically significant selection of a more-resistant C. albicans strain over multiple courses of treatment. Interestingly, MICs reached only 8.0 microg/ml, even though doses of 400 mg of fluconazole were necessary for clinical cure.
机译:通过抗真菌药敏试验和DNA亚型分析,评估了在两年期间接受氟康唑治疗口咽念珠菌病的AIDS患者中,每种感染的五个白色念珠菌菌落,并将其与临床反应相关联,以确定是否存在更多具有临床意义的选择对多种感染具有耐药性的白色念珠菌。从38名表现出84次感染发作的患者中总共获得534株白色念珠菌分离株。抗真菌药敏试验表明,93%的分离物的MIC≥8.0微克/毫升,而7%的分离物的MIC≥64微克/毫升。 DNA亚型揭示了70种不同的亚型,其中78%的一种感染患者表现出一种DNA亚型,80%的一种以上感染患者表现出多种DNA亚型。此外,患有多次感染的患者的CD4计数低于单一感染的患者。单一感染组和多重感染组之间关于DNA亚型的数量和CD4计数的差异均具有统计学意义。在74例可评估的感染中,除三名最终对大剂量氟康唑有最终反应的患者外,所有患者均已成功用常规剂量(每天100 mg)的氟康唑治疗。在多个疗程中,只有一名患者可能显示出对白念珠菌耐药性更高的临床选择。有趣的是,即使临床治愈需要400 mg氟康唑的剂量,MIC也仅为8.0 microg / ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号